Angelman Syndrome Foundation Making Strides in Awareness and Treatment
ASF Walk Raises Millions for Angelman Syndrome Research
The Angelman Syndrome Foundation (ASF) has consistently made significant progress in raising awareness and funding research for Angelman syndrome, a rare genetic condition that affects children and adults. Since 1999, the ASF Walk has raised an impressive $195 million, making a substantial impact on the lives of those affected by the condition.
Research Investments Fueling Advancements
The ASF has invested over $158 million in Angelman syndrome research to date, supporting groundbreaking projects that aim to improve diagnosis, treatment, and ultimately find a cure. This investment has led to significant advancements in understanding the condition and developing potential therapies.
FAST: Leading Patient Advocacy and Research
The Foundation for Angelman Syndrome Therapeutics (FAST) is another leading patient advocacy organization dedicated to curing Angelman syndrome. FAST works tirelessly to connect patients, families, and researchers, and to advocate for policies that support the Angelman syndrome community.
Research Symposium Fosters Collaboration
FAST's Research Symposium, an annual event, brings together an exceptional group of researchers and clinicians to share the latest findings and discuss promising avenues for future research. The symposium fosters collaboration and exchange of ideas, further accelerating the pace of progress towards a cure for Angelman syndrome.
Conclusion
The Angelman Syndrome Foundation and FAST are making a profound impact on the lives of those affected by Angelman syndrome. Their unwavering commitment to raising awareness, funding research, and advocating for patient needs is instrumental in driving progress towards a brighter future for all who face this rare and challenging condition.
Comments